Literature DB >> 11768158

Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice.

T Gilat1, A Leikin-Frenkel, L Goldiner, H Laufer, Z Halpern, F M Konikoff.   

Abstract

We have recently synthesized fatty acid bile acid conjugates (FABAC) that were able to reduce and retard cholesterol crystallization in model and human biles. When given orally, they prevented the formation of cholesterol crystals in the bile of hamsters. The aim of the present study was to determine whether the FABAC are cholesterol solubilizers, whether they can dissolve pre-existing crystals, whether they can prevent the formation of cholesterol gallstones, and to investigate the optimal type of bond between the fatty acid and bile acid. The presence of cholesterol crystals was determined by light microscopy, and the total crystal mass of precipitated crystals was measured by chemical means. Inbred (C57J/L) mice on a lithogenic diet were used to evaluate cholesterol crystal formation, dissolution, and gallstone formation in vivo. Arachidyl amido cholanoic acid (Aramchol) was the FABAC used in the present experiments. At equimolar amounts, the cholesterol-solubilizing capacity of Aramchol was higher than that of taurocholate and similar to that of phosphatidylcholine. The addition of Aramchol dissolved approximately 50% of pre-existing crystals in model bile solutions. The same phenomenon was demonstrated in human bile ex vivo, with a dose-response effect. All inbred mice developed cholesterol crystals in bile after 10-14 d on the lithogenic diet. Thereafter, supplementation of the diet with Aramchol progressively reduced the proportion of mice with crystals to 25% after 28 d. On the lithogenic diet, 100% of inbred mice developed cholesterol gallstones in the gallbladder by day 21. None of the mice whose diet was supplemented with 0.5 mg or 1.0 mg of Aramchol/d developed stones or crystals. FABAC are a new class of molecules that are cholesterol solubilizers and which are able to dissolve cholesterol crystals in bile. Upon oral administration, they dissolve pre-existing cholesterol crystals and prevent the formation of gallstones in gallstone-susceptible mice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11768158     DOI: 10.1007/s11745-001-0824-3

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  21 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

2.  A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity.

Authors:  L L ABEL; B B LEVY; B B BRODIE; F E KENDALL
Journal:  J Biol Chem       Date:  1952-03       Impact factor: 5.157

Review 3.  Phospholipid vesicles and other cholesterol carriers in bile.

Authors:  T Gilat; G J Sömjen
Journal:  Biochim Biophys Acta       Date:  1996-06-10

4.  Safety and efficacy of repeated shockwave lithotripsy of gallstones with and without adjuvant bile acid therapy.

Authors:  G Sauter; G A Kullak-Ublick; R Schumacher; J Janssen; L Greiner; B Brand; E F Stange; K Wengler; H Lochs; A Freytag; A Wissing; J Holl; M Sackmann; G Paumgartner
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

Review 5.  Gallstones during octreotide therapy.

Authors:  R H Dowling; S H Hussaini; G M Murphy; J A Wass
Journal:  Digestion       Date:  1993       Impact factor: 3.216

6.  Fatty acid bile acid conjugates (FABACs)--new molecules for the prevention of cholesterol crystallisation in bile.

Authors:  T Gilat; G J Somjen; Y Mazur; A Leikin-Frenkel; R Rosenberg; Z Halpern; F Konikoff
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

7.  Gall stone recurrence and its prevention: the British/Belgian Gall Stone Study Group's post-dissolution trial.

Authors:  K A Hood; D Gleeson; D C Ruppin; R H Dowling
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

8.  Filamentous, helical, and tubular microstructures during cholesterol crystallization from bile. Evidence that cholesterol does not nucleate classic monohydrate plates.

Authors:  F M Konikoff; D S Chung; J M Donovan; D M Small; M C Carey
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

9.  Effect of phospholipids and bile acids on cholesterol nucleation time and vesicular/micellar cholesterol in gallbladder bile of patients with cholesterol stones.

Authors:  D Jüngst; T Lang; P Huber; V Lange; G Paumgartner
Journal:  J Lipid Res       Date:  1993-09       Impact factor: 5.922

10.  Novel derivatives of 3 alpha,7 alpha-dihydroxy-5 beta-cholan-24-oic acid (chenodeoxycholic acid) and 3 alpha,7 beta-dihydroxy-5 beta-cholan-24-oic acid (ursodeoxycholic acid).

Authors:  D Kritchevsky; G Poli; C Scolastico; C R Sirtori
Journal:  Steroids       Date:  1986-01       Impact factor: 2.668

View more
  3 in total

Review 1.  Bile acids: regulation of synthesis.

Authors:  John Y L Chiang
Journal:  J Lipid Res       Date:  2009-04-03       Impact factor: 5.922

2.  ABCA1-dependent but apoA-I-independent cholesterol efflux mediated by fatty acid-bile acid conjugates (FABACs).

Authors:  Ilana Goldiner; Astrid E van der Velde; Kristin E Vandenberghe; Michel A van Wijland; Zamir Halpern; Tuvia Gilat; Fred M Konikoff; Robert Jan Veldman; Albert K Groen
Journal:  Biochem J       Date:  2006-06-15       Impact factor: 3.857

Review 3.  Current and future pharmacological therapies for NAFLD/NASH.

Authors:  Yoshio Sumida; Masashi Yoneda
Journal:  J Gastroenterol       Date:  2017-12-16       Impact factor: 7.527

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.